

Timothy B Niewold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8872035/publications.pdf>

Version: 2024-02-01

190
papers

11,323
citations

20759

60
h-index

34900

98
g-index

202
all docs

202
docs citations

202
times ranked

11878
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. <i>Immunity</i> , 2018, 49, 725-739.e6.	6.6	661
2	High serum IFN- γ activity is a heritable risk factor for systemic lupus erythematosus. <i>Genes and Immunity</i> , 2007, 8, 492-502.	2.2	390
3	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
4	Association of the IRF5 risk haplotype with high serum interferon- γ activity in systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 2481-2487.	6.7	246
5	Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. <i>Nature Genetics</i> , 2011, 43, 253-258.	9.4	242
6	End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With <i>APOL1</i> . <i>Arthritis and Rheumatology</i> , 2014, 66, 390-396.	2.9	242
7	Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. <i>Genes and Immunity</i> , 2011, 12, 270-279.	2.2	226
8	Type I interferon in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2018, 14, 214-228.	3.5	226
9	Network analysis of associations between serum interferon- γ activity, autoantibodies, and clinical features in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 1044-1053.	6.7	222
10	Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN- γ in Lupus Patients In Vivo. <i>Journal of Immunology</i> , 2009, 182, 34-38.	0.4	210
11	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2014-2021.	0.5	200
12	The Unexplained Female Predominance of Systemic Lupus Erythematosus: Clues from Genetic and Cytokine Studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 42-49.	2.9	199
13	Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1569-1574.	0.5	185
14	Immunogenetics of systemic lupus erythematosus: A comprehensive review. <i>Journal of Autoimmunity</i> , 2015, 64, 125-136.	3.0	182
15	Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility. <i>PLoS Genetics</i> , 2011, 7, e1002079.	1.5	181
16	Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study. <i>American Journal of Human Genetics</i> , 2012, 90, 648-660.	2.6	161
17	Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. <i>Clinical Rheumatology</i> , 2005, 24, 178-181.	1.0	159
18	Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN- γ and Serologic Autoimmunity in Lupus Patients. <i>Journal of Immunology</i> , 2011, 187, 1298-1303.	0.4	143

#	ARTICLE	IF	CITATIONS
19	Augmented interferon α pathway activation in patients with Sjögren's syndrome treated with etanercept. <i>Arthritis and Rheumatism</i> , 2007, 56, 3995-4004.	6.7	140
20	Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon α activity in lupus patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 553-561.	6.7	139
21	Interferon Alpha as a Primary Pathogenic Factor in Human Lupus. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 887-892.	0.5	134
22	Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 193-201.	0.2	132
23	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019, 21, 107.	1.6	129
24	IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 463-469.	0.5	127
25	Elevated serum interferon α activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty-six months of therapy. <i>Arthritis and Rheumatism</i> , 2009, 60, 1815-1824.	6.7	119
26	Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1752-1757.	0.5	110
27	Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. <i>Arthritis and Rheumatism</i> , 2011, 63, 3493-3501.	6.7	109
28	Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production. <i>PLoS Genetics</i> , 2013, 9, e1003222.	1.5	107
29	MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2013, 9, e1003336.	1.5	107
30	The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. <i>Gene</i> , 2016, 576, 14-21.	1.0	106
31	Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations. <i>PLoS ONE</i> , 2010, 5, e9088.	1.1	105
32	Type I interferon in the pathogenesis of systemic lupus erythematosus. <i>Current Opinion in Immunology</i> , 2020, 67, 87-94.	2.4	104
33	Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R151.	1.6	103
34	CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2017, 127, 1271-1283.	3.9	100
35	Fine mapping of Xq28: both <i>MECP2</i> and <i>IRAK1</i> contribute to risk for systemic lupus erythematosus in multiple ancestral groups. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 437-444.	0.5	97
36	The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. <i>Gene</i> , 2018, 668, 59-72.	1.0	94

#	ARTICLE	IF	CITATIONS
37	African-Derived Genetic Polymorphisms in <i>TNFAIP3</i> Mediate Risk for Autoimmunity. <i>Journal of Immunology</i> , 2010, 184, 7001-7009.	0.4	93
38	Age- and gender-specific modulation of serum osteopontin and interferon- λ by osteopontin genotype in systemic lupus erythematosus. <i>Genes and Immunity</i> , 2009, 10, 487-494.	2.2	92
39	Interferon Alpha in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-8.	3.0	91
40	A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. <i>EMBO Molecular Medicine</i> , 2011, 3, 142-152.	3.3	91
41	Interferon regulatory factors in human lupus pathogenesis. <i>Translational Research</i> , 2011, 157, 326-331.	2.2	88
42	Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 694-699.	0.5	87
43	Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 541-546.	6.7	84
44	The <i>PTPN22</i> C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon- λ activity and low tumor necrosis factor λ levels in patients with lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 2818-2823.	6.7	82
45	Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2013, 4, 319.	2.2	81
46	Rheumatologic Manifestations of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 463-473.	0.8	80
47	Brief Report: Large-scale analysis of tumor necrosis factor λ levels in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2947-2952.	6.7	76
48	Age- and sex-related patterns of serum interferon- λ activity in lupus families. <i>Arthritis and Rheumatism</i> , 2008, 58, 2113-2119.	6.7	74
49	Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis. <i>Pediatrics</i> , 2011, 127, e1239-e1246.	1.0	74
50	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	1.4	74
51	Identification of a Systemic Lupus Erythematosus Susceptibility Locus at 11p13 between PDHX and CD44 in a Multiethnic Study. <i>American Journal of Human Genetics</i> , 2011, 88, 83-91.	2.6	72
52	TLR7 and TLR8 Differentially Activate the IRF and NF- κ B Pathways in Specific Cell Types to Promote Inflammation. <i>ImmunoHorizons</i> , 2020, 4, 93-107.	0.8	72
53	Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. <i>Journal of Autoimmunity</i> , 2015, 60, 51-58.	3.0	71
54	The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. <i>Gut</i> , 2016, 65, 456-464.	6.1	71

#	ARTICLE	IF	CITATIONS
55	Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian and European populations. <i>Arthritis and Rheumatism</i> , 2012, 64, 3687-3694.	6.7	70
56	ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1743-1754.	3.0	70
57	Association of two independent functional risk haplotypes in <i>TNIP1</i> with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3695-3705.	6.7	69
58	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , 2021, 232, 13-36.	2.2	69
59	Pathogenic Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1933-1945.	2.9	68
60	Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 313, 48-53.	0.3	64
61	Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. <i>Arthritis and Rheumatism</i> , 2011, 63, 2396-2406.	6.7	63
62	Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. <i>Arthritis and Rheumatism</i> , 2010, 62, 2813-2822.	6.7	60
63	Genetic regulation of serum cytokines in systemic lupus erythematosus. <i>Translational Research</i> , 2010, 155, 109-117.	2.2	60
64	Variation in the <i>ICAM1</i> – <i>ICAM4</i> – <i>ICAM5</i> locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1809-1814.	0.5	60
65	B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. <i>Arthritis and Rheumatism</i> , 2011, 63, 3931-3941.	6.7	59
66	Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription. <i>American Journal of Human Genetics</i> , 2014, 94, 586-598.	2.6	59
67	Increased pretreatment serum IFN- γ ratio predicts non-response to tumour necrosis factor inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.5	59
68	Ocrelizumab: a step forward in the evolution of B-cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 889-895.	1.4	58
69	Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. <i>Genes and Immunity</i> , 2012, 13, 232-238.	2.2	58
70	PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes. <i>PLoS ONE</i> , 2013, 8, e69404.	1.1	57
71	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017, 69, 630-642.	2.9	56
72	Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 46-54.	0.2	55

#	ARTICLE	IF	CITATIONS
73	Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. <i>Genes and Immunity</i> , 2013, 14, 471-478.	2.2	54
74	Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 485-492.	6.7	53
75	Genetics of human lupus nephritis. <i>Clinical Immunology</i> , 2017, 185, 32-39.	1.4	53
76	Interferon Alpha-Induced Lupus. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 131-132.	0.5	52
77	Bone Health Issues in Sarcoidosis. <i>Current Rheumatology Reports</i> , 2011, 13, 265-272.	2.1	52
78	Evaluation of <i>TRAF6</i> in a large multi-ancestral lupus cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 1960-1969.	6.7	51
79	CheB is required for behavioural responses to negative stimuli during chemotaxis in <i>Bacillus subtilis</i> . <i>Molecular Microbiology</i> , 2000, 35, 44-57.	1.2	50
80	A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. <i>Genes and Immunity</i> , 2012, 13, 380-387.	2.2	50
81	Trans-Ancestral Studies Fine Map the SLE-Susceptibility Locus TNFSF4. <i>PLoS Genetics</i> , 2013, 9, e1003554.	1.5	50
82	Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients. <i>Frontiers in Immunology</i> , 2013, 4, 309.	2.2	50
83	Genetics of the type I interferon pathway in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 657-669.	0.3	49
84	Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015, 16, 2019-2034.	0.6	49
85	Inhibition of Interferon-beta Responses in Multiple Sclerosis Immune Cells Associated With High-Dose Statins. <i>Archives of Neurology</i> , 2012, 69, 1303.	4.9	47
86	Clinical Characteristics of Patients With Anti-Jo-1 Antibodies. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 254-255.	0.5	45
87	The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. <i>Translational Research</i> , 2012, 160, 321-331.	2.2	45
88	The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-11.	3.0	44
89	Advances in lupus genetics. <i>Current Opinion in Rheumatology</i> , 2015, 27, 440-447.	2.0	44
90	Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab. <i>American Journal of Kidney Diseases</i> , 2010, 56, e17-e21.	2.1	42

#	ARTICLE	IF	CITATIONS
91	Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete. <i>Lupus</i> , 2011, 20, 501-506.	0.8	41
92	Combined role of vitamin D status and <i>CYP24A1</i> in the transition to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 153-158.	0.5	40
93	Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy. <i>Lupus Science and Medicine</i> , 2017, 4, e000202.	1.1	39
94	Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	38
95	Brief Report: Interferon- γ Induction and Detection of Anti-RO, Anti-La, Anti-Sm, and Anti-RNP Autoantibodies by Autoantigen Microarray Analysis in Juvenile Dermatomyositis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2424-2429.	6.7	37
96	Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. <i>Journal of Autoimmunity</i> , 2021, 119, 102615.	3.0	37
97	Association of <i>PPP2CA</i> polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. <i>Arthritis and Rheumatism</i> , 2011, 63, 2755-2763.	6.7	36
98	Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3383-3387.	6.7	36
99	Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression. <i>PLoS Genetics</i> , 2013, 9, e1003870.	1.5	36
100	Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients. <i>Gene</i> , 2016, 583, 90-101.	1.0	35
101	A plausibly causal functional lupus-associated risk variant in the <i>STAT1</i> – <i>STAT4</i> locus. <i>Human Molecular Genetics</i> , 2018, 27, 2392-2404.	1.4	34
102	Gene-Gene-Sex Interaction in Cytokine Gene Polymorphisms Revealed by Serum Interferon Alpha Phenotype in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2010, 157, 653-657.	0.9	33
103	Osteopontin Alleles Are Associated with Clinical Characteristics in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-6.	3.0	33
104	Interferon regulatory factors: critical mediators of human lupus. <i>Translational Research</i> , 2015, 165, 283-295.	2.2	33
105	Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, R18.	1.6	32
106	Genetic Ancestry, Serum Interferon- γ Activity, and Autoantibodies in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1238-1240.	1.0	29
107	Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. <i>Cytokine</i> , 2013, 61, 906-911.	1.4	28
108	Functional genetic polymorphisms in <i>ILT3</i> are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 596-601.	0.5	28

#	ARTICLE	IF	CITATIONS
109	Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 747-757.	2.0	28
110	Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1022-1029.	0.5	27
111	Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 143.	0.9	26
112	Promoter Variant of <i>PIK3C3</i> Is Associated with Autoimmunity against Ro and Sm Epitopes in African-American Lupus Patients. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	25
113	Linkage of Type I Interferon Activity and TNF-Alpha Levels in Serum with Sarcoidosis Manifestations and Ancestry. <i>PLoS ONE</i> , 2011, 6, e29126.	1.1	25
114	The Autoimmune Disease Risk Allele of UBE2L3 in African American Patients with Systemic Lupus Erythematosus: A Recessive Effect Upon Subphenotypes. <i>Journal of Rheumatology</i> , 2012, 39, 73-78.	1.0	25
115	Type I Interferon in Human Autoimmunity. <i>Frontiers in Immunology</i> , 2014, 5, 306.	2.2	25
116	Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM. <i>Human Molecular Genetics</i> , 2014, 23, 4161-4176.	1.4	25
117	Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 117-124.	1.0	25
118	Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. <i>Lupus</i> , 2014, 23, 881-888.	0.8	24
119	Lupus-Associated Functional Polymorphism in <i>PNP</i> Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. <i>Arthritis and Rheumatology</i> , 2017, 69, 2328-2337.	2.9	24
120	Concomitant interferon- γ therapy and tumor necrosis factor γ inhibition for rheumatoid arthritis and hepatitis C. <i>Arthritis and Rheumatism</i> , 2006, 54, 2335-2337.	6.7	23
121	Differential Expression of miR-4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). <i>Journal of Cellular Physiology</i> , 2017, 232, 1326-1336.	2.0	23
122	Dysregulation of antiviral helicase pathways in systemic lupus erythematosus. <i>Frontiers in Genetics</i> , 2014, 5, 418.	1.1	22
123	Type I Interferons in Autoimmunity. <i>Journal of Investigative Dermatology</i> , 2022, 142, 793-803.	0.3	21
124	Novel genetic associations with interferon in systemic lupus erythematosus identified by replication and fine-mapping of trait-stratified genome-wide screen. <i>Cytokine</i> , 2020, 132, 154631.	1.4	19
125	Sirukumab: a novel therapy for lupus nephritis?. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1449-1455.	1.9	18
126	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. <i>Frontiers in Immunology</i> , 2013, 4, 238.	2.2	17

#	ARTICLE	IF	CITATIONS
127	Brief Report: A Novel <i>ELANE</i> Mutation Associated With Inflammatory Arthritis, Defective NETosis, and Recurrent Parvovirus Infection. <i>Arthritis and Rheumatology</i> , 2017, 69, 2396-2401.	2.9	17
128	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2007-2013.	0.5	16
129	Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. <i>Journal of Rheumatology</i> , 2013, 40, 842-849.	1.0	15
130	Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. <i>Lupus</i> , 2013, 22, 1523-1525.	0.8	15
131	A Successful Trial for Lupus – How Good Is Good Enough?. <i>New England Journal of Medicine</i> , 2020, 382, 287-288.	13.9	15
132	Targeting type I interferon in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2016, 12, 377-378.	3.5	14
133	Familial Aggregation of Childhood and Adulthood Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1147-1151.	1.5	14
134	Type I interferon antagonists in clinical development for lupus. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1025-1041.	1.9	14
135	Immunological Biomarkers in Dermatomyositis. <i>Current Rheumatology Reports</i> , 2015, 17, 68.	2.1	13
136	Gene-Expression-Guided Selection of Candidate Loci and Molecular Phenotype Analyses Enhance Genetic Discovery in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	12
137	Familial Aggregation of High Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	12
138	Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds. <i>Lupus Science and Medicine</i> , 2018, 5, e000246.	1.1	12
139	Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 1384.	2.2	12
140	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	1.6	12
141	Lessons from precision medicine in rheumatology. <i>Multiple Sclerosis Journal</i> , 2020, 26, 533-539.	1.4	11
142	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. <i>Journal of Rheumatology</i> , 2022, 49, 388-397.	1.0	11
143	Post-streptococcal reactive arthritis and glomerulonephritis in an adult. <i>Clinical Rheumatology</i> , 2003, 22, 350-352.	1.0	10
144	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015, 161, 157-162.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opinion on Investigational Drugs, 2016, 25, 573-583.	1.9	10
146	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.5	10
147	Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy. Pharmaceutical Medicine, 2017, 31, 81-88.	1.0	10
148	Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus. ACR Open Rheumatology, 2019, 1, 499-506.	0.9	10
149	Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange. American Journal of Hematology, 2006, 81, 454-457.	2.0	9
150	Lenalidomide for the Treatment of Cryoglobulinemia and Undifferentiated Spondyloarthritis in a Patient With Multiple Myeloma. Journal of Clinical Rheumatology, 2010, 16, 90-91.	0.5	9
151	Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. Translational Research, 2022, 244, 47-55.	2.2	9
152	Single-cell expression quantitative trait loci (eQTL) analysis of SLE-risk loci in lupus patient monocytes. Arthritis Research and Therapy, 2021, 23, 290.	1.6	8
153	Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study. Autoimmune Diseases, 2017, 2017, 1-5.	2.7	7
154	T Cells in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2021, 47, 379-393.	0.8	7
155	Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. Clinical Rheumatology, 2018, 37, 1011-1015.	1.0	5
156	Dynamics of pulse wave velocity and vascular augmentation index in association with endothelial progenitor cells in SLE. Lupus Science and Medicine, 2016, 3, e000185.	1.1	4
157	By CyTOF. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1423-1424.	1.1	4
158	Manifestations of systemic lupus erythematosus in female patients with polysomy X: Possible roles of chromosome X. Modern Rheumatology, 2019, 29, 192-194.	0.9	4
159	Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies. Rheumatology International, 2021, 41, 219-225.	1.5	4
160	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	1.1	4
161	Artificial intelligence and deep learning to map immune cell types in inflamed human tissue. Journal of Immunological Methods, 2022, 505, 113233.	0.6	4
162	Cytokines in Systemic Lupus Erythematosus 2011. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-1.	3.0	3

#	ARTICLE	IF	CITATIONS
163	78-Year-Old Woman With Fever, Weight Loss, and Rash. <i>Mayo Clinic Proceedings</i> , 2003, 78, 635-638.	1.4	2
164	27-Year-Old Woman With Numbness and Weakness of the Extremities. <i>Mayo Clinic Proceedings</i> , 2003, 78, 95-98.	1.4	2
165	Cytokines in Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-2.	3.0	2
166	Autoimmune Disease Genetics 2013. <i>Journal of Immunology Research</i> , 2014, 2014, 1-2.	0.9	2
167	Cytokines in Lupus. , 2019, , 137-152.		2
168	Axonal dysfunction is associated with interferon- β levels in childhood-onset systemic lupus erythematosus: a multivoxel magnetic resonance spectroscopy study. <i>Rheumatology</i> , 2022, 61, 1529-1537.	0.9	2
169	59-Year-Old Woman With Progressive Dyspnea on Exertion. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1567-1570.	1.4	1
170	TNF Inhibition As Novel Therapy For Refractory Sarcoidosis: Long Term Follow Up. , 2010, , .		1
171	52-Week Trial Results Of Adalimumab As Novel Therapy For Refractory, Progressive Pulmonary Sarcoidosis. , 2010, , .		1
172	Autoimmune Disease Genetics. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	1
173	Cytokines and Interferons in Lupus. , 2013, , 62-75.		1
174	When pregnancy tames the wolf. <i>Journal of Experimental Medicine</i> , 2019, 216, 1012-1013.	4.2	1
175	Type I interferon. <i>Cytokine</i> , 2020, 132, 155109.	1.4	1
176	Stabilizing the Kidney's Skeleton. <i>Science Translational Medicine</i> , 2011, 3, .	5.8	1
177	Is Rheumatoid Arthritis a Causal Factor in Cardiovascular Disease?. <i>Arthritis and Rheumatology</i> , 2022, 74, 1612-1614.	2.9	1
178	Cytokines: Diagnostic and Clinical Applications. , 2016, , 357-364.		0
179	The role of interferons in systemic lupus erythematosus. , 2021, , 171-178.		0
180	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. <i>Blood</i> , 2010, 116, 3694-3694.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Genetic Tug of War in the Immune System. Science Translational Medicine, 2011, 3, .	5.8	0
182	Actionable Pharmacogenetics for Epilepsy. Science Translational Medicine, 2011, 3, .	5.8	0
183	Decoding Melanoma. Science Translational Medicine, 2011, 3, .	5.8	0
184	Inheriting Disease Severity. Science Translational Medicine, 2011, 03, .	5.8	0
185	Channeling Cognitive Performance. Science Translational Medicine, 2011, 3, .	5.8	0
186	Thinking Globally About Asthma. Science Translational Medicine, 2011, 3, .	5.8	0
187	One Size Doesn't Fit All. Science Translational Medicine, 2011, 3, .	5.8	0
188	It's What You Do that Matters. Science Translational Medicine, 2011, 3, .	5.8	0
189	How Do You Handle Your Antibodies?. Science Translational Medicine, 2012, 4, .	5.8	0
190	Allergic to the Cold. Science Translational Medicine, 2012, 4, .	5.8	0